Thoracic irradiation (RT) is a major component of therapy for many patients with tumors of the breast, lung, esophagus, thymus and mediastinal lymphatics. In these patients, RT-induced pulmonary injury is one of the most common treatment-related toxicities. Despite the large number of patients that receive thoracic RT, the biologic and physical determinants of RT-induced lung injury are not fully understood. There are no accepted means of predicting, prior to delivery of RT, what the physiologic consequences of the RT will be. In the prior funding period, we successfully exploited functional lung imaging and three-dimensional (3D) radiation treatment planning tools to address this issue. Using single photon emission computed tomography (SPECT) lung perfusion scans as an assessment of regional function, we defined the dose-response curve for RT-induced regional lung injury, and its temporal nature. Preliminary data suggests that RT- induced changes in whole lung function can be quantitatively related to the sum of regional injuries. We established the importance of understanding the RT dose distribution relative to the functioning (i.e., perfused) regions of the lung in addition to the anatomical CT-defined lung, and the importance of pre-RT whole lung function, in predicting RT-induced whole lung injury. Based on our work, we have developed algorithms that should be predictive for RT-induced changes in lung function. Furthermore, we and others have demonstrated that TGF-beta (transforming growth factor-beta) may be a marker to identify patients who are predisposed to develop RT-induced lung injury. The current proposal builds on our prior work to address persistent/new issues. First, we will prospectively test the ability of our algorithms (based on the dose distribution within the anatomic and functional lung, and pre-RT pulmonary function) to predict which patients are at relatively high vs. low risk of experiencing RT-induced reductions in whole lung function. Second, we will further study the relationship between regional lung injury (assessed with SPECT perfusion scans) and changes in whole lung function. Whole lung function will be assessed, as done previously, by changes in pulmonary function tests and pulmonary symptoms. In addition, we will assess exercise tolerance by monitoring changes m the distance the patient can walk in six minutes. This six minute walk distance is a more clinically and functionally relevant metric since it measures overall exercise capacity. Third, we will prospectively assess the impact of TGF-beta on RT- induced lung dysfunction. This project will increase understanding of the dosimetric, physiologic and biologic determinants of RT-induced lung injury. The development, testing and validation of such predictive algorithms will improve patient care by reducing the incidence of lung injury and facilitate """"""""safe"""""""" dose escalation for intrathoracic cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA069579-07
Application #
6621746
Study Section
Special Emphasis Panel (ZRG1-CONC (01))
Program Officer
Stone, Helen B
Project Start
1996-05-01
Project End
2004-12-31
Budget Start
2003-01-01
Budget End
2003-12-31
Support Year
7
Fiscal Year
2003
Total Cost
$274,120
Indirect Cost
Name
Duke University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Wang, Kyle; Pearlstein, Kevin A; Patchett, Nicholas D et al. (2017) Heart dosimetric analysis of three types of cardiac toxicity in patients treated on dose-escalation trials for Stage III non-small-cell lung cancer. Radiother Oncol 125:293-300
Wang, Kyle; Eblan, Michael J; Deal, Allison M et al. (2017) Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy. J Clin Oncol 35:1387-1394
Warner, Andrew; Dahele, Max; Hu, Bo et al. (2016) Factors Associated With Early Mortality in Patients Treated With Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 94:612-20
Rodrigues, George; Oberije, Cary; Senan, Suresh et al. (2015) Is intermediate radiation dose escalation with concurrent chemotherapy for stage III non-small-cell lung cancer beneficial? A multi-institutional propensity score matched analysis. Int J Radiat Oncol Biol Phys 91:133-9
Diot, Quentin; Marks, Lawrence B; Bentzen, Soren M et al. (2014) Comparison of radiation-induced normal lung tissue density changes for patients from multiple institutions receiving conventional or hypofractionated treatments. Int J Radiat Oncol Biol Phys 89:626-32
Zagar, Timothy M; Marks, Lawrence B (2013) Breast cancer: risk of heart disease after radiotherapy-cause for concern. Nat Rev Clin Oncol 10:310-2
Palma, David A; Senan, Suresh; Oberije, Cary et al. (2013) Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: an individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 87:690-6
Palma, David A; Senan, Suresh; Tsujino, Kayoko et al. (2013) Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 85:444-50
Kelsey, Chris R; Jackson, Isabel L; Langdon, Scott et al. (2013) Analysis of single nucleotide polymorphisms and radiation sensitivity of the lung assessed with an objective radiologic endpoin. Clin Lung Cancer 14:267-74
Lawrence, Michael V; Saynak, Mert; Fried, David V et al. (2012) Assessing the impact of radiation-induced changes in soft tissue density ? thickness on the study of radiation-induced perfusion changes in the lung and heart. Med Phys 39:7644-9

Showing the most recent 10 out of 37 publications